Precision’s chronic HBV gene therapy; plus Blaze and ASGCT highlights

Precision BioSciences Inc. (NASDAQ:DTIL) revealed in Molecular Therapy that its engineered HBV-targeted nuclease reduced levels of the hepatitis B extrachromosomal genome and surface antigen in mouse and non-human primate models of chronic infection.

The gene therapy also reduced extrachromosomal DNA and surface antigen levels by 85% and 77%, respectively, in HBV-infected primary human hepatocytes. ...